Cargando…
Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760548/ https://www.ncbi.nlm.nih.gov/pubmed/30700792 http://dx.doi.org/10.1038/s41409-019-0454-z |
| _version_ | 1783453887413354496 |
|---|---|
| author | Abuelgasim, Khadega A. Alzahrani, Mohsen Alsharhan, Yousef Khairi, Moataz Hommady, Mohammed Gmati, Giamal Salama, Hind Ali, Osama Alahmari, Bader Masuadi, Emad M. Alaskar, Ahmed Alhejazi, Ayman Damlaj, Moussab |
| author_facet | Abuelgasim, Khadega A. Alzahrani, Mohsen Alsharhan, Yousef Khairi, Moataz Hommady, Mohammed Gmati, Giamal Salama, Hind Ali, Osama Alahmari, Bader Masuadi, Emad M. Alaskar, Ahmed Alhejazi, Ayman Damlaj, Moussab |
| author_sort | Abuelgasim, Khadega A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6760548 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-67605482019-09-26 Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma Abuelgasim, Khadega A. Alzahrani, Mohsen Alsharhan, Yousef Khairi, Moataz Hommady, Mohammed Gmati, Giamal Salama, Hind Ali, Osama Alahmari, Bader Masuadi, Emad M. Alaskar, Ahmed Alhejazi, Ayman Damlaj, Moussab Bone Marrow Transplant Correspondence Nature Publishing Group UK 2019-01-30 2019 /pmc/articles/PMC6760548/ /pubmed/30700792 http://dx.doi.org/10.1038/s41409-019-0454-z Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Correspondence Abuelgasim, Khadega A. Alzahrani, Mohsen Alsharhan, Yousef Khairi, Moataz Hommady, Mohammed Gmati, Giamal Salama, Hind Ali, Osama Alahmari, Bader Masuadi, Emad M. Alaskar, Ahmed Alhejazi, Ayman Damlaj, Moussab Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma |
| title | Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma |
| title_full | Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma |
| title_fullStr | Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma |
| title_full_unstemmed | Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma |
| title_short | Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma |
| title_sort | chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical hodgkin lymphoma |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760548/ https://www.ncbi.nlm.nih.gov/pubmed/30700792 http://dx.doi.org/10.1038/s41409-019-0454-z |
| work_keys_str_mv | AT abuelgasimkhadegaa chemoimmunotherapywithbrentuximabvedotincombinedwithifosfamidegemcitabineandvinorelbineishighlyactiveinrelapsedorrefractoryclassicalhodgkinlymphoma AT alzahranimohsen chemoimmunotherapywithbrentuximabvedotincombinedwithifosfamidegemcitabineandvinorelbineishighlyactiveinrelapsedorrefractoryclassicalhodgkinlymphoma AT alsharhanyousef chemoimmunotherapywithbrentuximabvedotincombinedwithifosfamidegemcitabineandvinorelbineishighlyactiveinrelapsedorrefractoryclassicalhodgkinlymphoma AT khairimoataz chemoimmunotherapywithbrentuximabvedotincombinedwithifosfamidegemcitabineandvinorelbineishighlyactiveinrelapsedorrefractoryclassicalhodgkinlymphoma AT hommadymohammed chemoimmunotherapywithbrentuximabvedotincombinedwithifosfamidegemcitabineandvinorelbineishighlyactiveinrelapsedorrefractoryclassicalhodgkinlymphoma AT gmatigiamal chemoimmunotherapywithbrentuximabvedotincombinedwithifosfamidegemcitabineandvinorelbineishighlyactiveinrelapsedorrefractoryclassicalhodgkinlymphoma AT salamahind chemoimmunotherapywithbrentuximabvedotincombinedwithifosfamidegemcitabineandvinorelbineishighlyactiveinrelapsedorrefractoryclassicalhodgkinlymphoma AT aliosama chemoimmunotherapywithbrentuximabvedotincombinedwithifosfamidegemcitabineandvinorelbineishighlyactiveinrelapsedorrefractoryclassicalhodgkinlymphoma AT alahmaribader chemoimmunotherapywithbrentuximabvedotincombinedwithifosfamidegemcitabineandvinorelbineishighlyactiveinrelapsedorrefractoryclassicalhodgkinlymphoma AT masuadiemadm chemoimmunotherapywithbrentuximabvedotincombinedwithifosfamidegemcitabineandvinorelbineishighlyactiveinrelapsedorrefractoryclassicalhodgkinlymphoma AT alaskarahmed chemoimmunotherapywithbrentuximabvedotincombinedwithifosfamidegemcitabineandvinorelbineishighlyactiveinrelapsedorrefractoryclassicalhodgkinlymphoma AT alhejaziayman chemoimmunotherapywithbrentuximabvedotincombinedwithifosfamidegemcitabineandvinorelbineishighlyactiveinrelapsedorrefractoryclassicalhodgkinlymphoma AT damlajmoussab chemoimmunotherapywithbrentuximabvedotincombinedwithifosfamidegemcitabineandvinorelbineishighlyactiveinrelapsedorrefractoryclassicalhodgkinlymphoma |